XPNPEP2

XPNPEP2 encodes membrane-bound aminopeptidase P (APP), an X-linked (Xq25) ectoenzyme largely restricted to vascular endothelia and brush border epithelia that hydrolyzes N-terminal Xaa-Pro bonds through a metal-dependent 'pita-bread fold' catalytic architecture, enabling it to inactivate vasoactive peptides including bradykinin (PMID:10871044). Beyond bradykinin, APP participates in the N-terminal truncation of neuropeptide Y as one of several Xaa-Pro peptidases (PMID:17223229). Its expression is governed by an upstream enhancer (-2,502 to -2,238 bp) acting on a minimal promoter (-338 to -147 bp), and a functional ATG haplotype carrying the C-2399A variant — which falls within an HNF4-responsive enhancer element — lowers reporter activity and plasma APP activity (PMID:21898657). Reduced APP activity from this genetic variation, together with non-specific inhibition of recombinant APP by ACE inhibitors, predisposes to ACE inhibitor-induced angioedema, an association linked genetically to the XPNPEP2 locus and showing sex-dependent penetrance (PMID:16175507, PMID:17003818, PMID:20625347). Independent of its peptidase role, XPNPEP2 is required for endothelial function and angiogenesis: it interacts with the mitochondrial ADP/ATP translocator SLC25A6 and protects it from SIAH1-mediated ubiquitin-proteasome degradation, thereby sustaining mitochondria-associated membranes, ATP production, and respiratory chain integrity, and its loss in mice impairs vascular development, wound healing, and tumor growth (PMID:41573684). XPNPEP2 also promotes epithelial-mesenchymal transition and cancer cell invasion and metastasis (PMID:28670957).

1. 2000 Medium

   Established the molecular identity, chromosomal location, and catalytic basis of XPNPEP2, defining it as a metal-dependent Xaa-Pro ectopeptidase capable of inactivating bradykinin.

   Evidence Chromosomal mapping by somatic cell hybrids and sequence-homology identification of catalytic residues against E. coli aminopeptidase

   PMID:10871044

   Open questions at the time

   • No experimental crystal structure of human APP
   • Physiological substrate repertoire beyond bradykinin not defined
   • Tissue distribution inferred, not quantified
2. 2000 Medium

   Showed that an Xq25 translocation physically disrupts XPNPEP2 and that the gene at least partially escapes X inactivation, addressing its genomic regulation.

   Evidence Breakpoint mapping and RT-PCR in translocation-bearing fibroblasts

   PMID:10894934

   Open questions at the time

   • Causal link between XPNPEP2 disruption and the premature ovarian failure phenotype not established
   • Extent of X-inactivation escape not quantified
3. 2005 High

   Linked XPNPEP2 genetic variation to a heritable plasma APP activity trait and to ACE inhibitor-induced angioedema, connecting enzyme dosage to a clinical adverse drug reaction.

   Evidence Genome-wide linkage (LOD 3.75), measured-genotype association in pedigrees, and case-control study

   PMID:16175507

   Open questions at the time

   • Mechanism by which the SNP reduces activity not yet resolved at this stage
   • Causal variant versus tagged variant not distinguished
4. 2006 Medium

   Demonstrated a direct enzymatic interaction by showing recombinant APP is inhibited by ACE inhibitors, providing a biochemical basis for the angioedema association.

   Evidence In vitro enzymatic inhibition assay with recombinant APP plus genetic association in hemodialysis patients

   PMID:17003818

   Open questions at the time

   • Inhibition described as non-specific; physiological relevance of in vitro potency unclear
   • Single-lab data
5. 2007 Medium

   Expanded the substrate scope of APP to include N-terminal truncation of neuropeptide Y, positioning it among several Xaa-Pro peptidases in neuropeptide metabolism.

   Evidence Selective inhibitor activity assays and MALDI-TOF MS of cleavage products in brain extracts and plasma

   PMID:17223229

   Open questions at the time

   • Relative contribution of XPNPEP2 versus other peptidases not quantified
   • In vivo relevance of NPY truncation by APP not tested
6. 2010 Medium

   Revealed sex-dependent regulation of APP activity and sex-specific penetrance of the angioedema-associated genotype, refining the genotype-phenotype relationship.

   Evidence Genotyping and serum APP activity assay in a case-control study with multivariate analysis

   PMID:20625347

   Open questions at the time

   • Molecular basis of sex difference not identified
   • Population-specific effects (black men) not mechanistically explained
7. 2011 High

   Defined the cis-regulatory architecture of XPNPEP2 and identified HNF4 as a trans-activator acting on the enhancer where the functional C-2399A variant resides, explaining how the ATG haplotype lowers expression and plasma activity.

   Evidence Promoter deletion/reporter assays, HNF4 binding prediction and overexpression reporter assay, and plasma APP activity in a case-control study

   PMID:21898657

   Open questions at the time

   • Direct HNF4 occupancy at the endogenous enhancer not shown (prediction-based)
   • Contribution of the other haplotype variants not individually dissected
8. 2015 Medium

   Placed Xpnpep2 in a pathway controlling extracellular matrix composition and ovarian follicle development, suggesting roles beyond circulating peptide catabolism.

   Evidence In vivo gestational CrVI exposure model with colocalization and expression profiling across developmental stages

   PMID:25568306

   Open questions at the time

   • Mechanism linking APP to collagen regulation not defined
   • Causality (regulator vs correlate) not established
9. 2017 Medium

   Demonstrated a pro-metastatic function for XPNPEP2, showing it drives invasion, migration, and EMT in cancer cells independent of proliferation.

   Evidence Overexpression in cervical cancer cell lines with invasion/migration and EMT assays plus xenograft metastasis model

   PMID:28670957

   Open questions at the time

   • Molecular effectors of EMT downstream of XPNPEP2 not identified
   • Whether catalytic activity is required not tested
10. 2018 Medium

    Reinforced the conserved Xaa-Pro catalytic mechanism by mutagenesis of the DXRY motif in bacterial orthologs, extrapolated to human XPNPEP2.

    Evidence Crystal structure, enzymatic assays, and DXRY motif mutagenesis in bacterial small aminopeptidases-P

    PMID:30536999

    Open questions at the time

    • Experiments performed on bacterial enzymes, not human XPNPEP2
    • Functional importance of the motif in the human enzyme not directly verified
11. 2023 Low

    Identified XPNPEP2 as the receptor for the tumor-homing peptide TMTP1 and documented a secreted serum form, linking the protein to selective targeting of metastatic cells.

    Evidence Western blot for secreted XPNPEP2 and ELISA in patient serum; receptor identity cited from prior work

    PMID:31296901

    Open questions at the time

    • No direct TMTP1 binding assay reported in this study
    • Origin and processing of the secreted form not characterized
12. 2026 High

    Established a peptidase-independent role for XPNPEP2 in endothelial mitochondrial homeostasis and angiogenesis through stabilization of SLC25A6, defining a new mechanistic axis.

    Evidence Knockout mouse model, endothelial functional assays, XPNPEP2-SLC25A6 Co-IP, SIAH1 degradation assay, and rescue experiments

    PMID:41573684

    Open questions at the time

    • Reciprocal validation and direct/indirect nature of the XPNPEP2-SLC25A6 interaction not fully resolved
    • Whether aminopeptidase catalytic activity is needed for SLC25A6 protection not determined
    • Mechanism by which XPNPEP2 blocks SIAH1-mediated ubiquitination unknown

• It remains unresolved whether the catalytic aminopeptidase activity of XPNPEP2 is required for its non-enzymatic roles in mitochondrial stabilization, EMT, and angiogenesis, and how its membrane-bound, secreted, and receptor functions are mechanistically integrated.
• No study dissociates catalytic from scaffolding functions
• Relationship between secreted and membrane forms uncharacterized
• Structural basis of SLC25A6 binding unknown